TW202506129A - 維貝隆(vibegron)用於治療膀胱過動症之用途 - Google Patents

維貝隆(vibegron)用於治療膀胱過動症之用途 Download PDF

Info

Publication number
TW202506129A
TW202506129A TW113116798A TW113116798A TW202506129A TW 202506129 A TW202506129 A TW 202506129A TW 113116798 A TW113116798 A TW 113116798A TW 113116798 A TW113116798 A TW 113116798A TW 202506129 A TW202506129 A TW 202506129A
Authority
TW
Taiwan
Prior art keywords
subject
vibelong
mmhg
individual
placebo
Prior art date
Application number
TW113116798A
Other languages
English (en)
Chinese (zh)
Inventor
保羅 小穆德
Original Assignee
瑞士商優洛凡特科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商優洛凡特科學公司 filed Critical 瑞士商優洛凡特科學公司
Publication of TW202506129A publication Critical patent/TW202506129A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW113116798A 2019-03-18 2020-03-18 維貝隆(vibegron)用於治療膀胱過動症之用途 TW202506129A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US62/820,230 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US62/830,302 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US62/842,435 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US62/885,767 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US62/897,019 2019-09-06
US201962904429P 2019-09-23 2019-09-23
US62/904,429 2019-09-23

Publications (1)

Publication Number Publication Date
TW202506129A true TW202506129A (zh) 2025-02-16

Family

ID=70166082

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113116798A TW202506129A (zh) 2019-03-18 2020-03-18 維貝隆(vibegron)用於治療膀胱過動症之用途
TW109109041A TW202102221A (zh) 2019-03-18 2020-03-18 維貝隆(vibegron)用於治療膀胱過動症之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109109041A TW202102221A (zh) 2019-03-18 2020-03-18 維貝隆(vibegron)用於治療膀胱過動症之用途

Country Status (14)

Country Link
US (1) US20230027066A1 (cg-RX-API-DMAC7.html)
EP (2) EP4763281A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022524576A (cg-RX-API-DMAC7.html)
KR (2) KR20260049872A (cg-RX-API-DMAC7.html)
CN (2) CN121489955A (cg-RX-API-DMAC7.html)
AU (2) AU2020243514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129024A1 (cg-RX-API-DMAC7.html)
IL (1) IL285910A (cg-RX-API-DMAC7.html)
MX (1) MX2021009488A (cg-RX-API-DMAC7.html)
PH (1) PH12021551975A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108810YA (cg-RX-API-DMAC7.html)
TW (2) TW202506129A (cg-RX-API-DMAC7.html)
WO (1) WO2020188505A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆(vibegron)於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍(vibegron)治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Kcnq2〜5チャネル関連疾患の予防および/または治療剤
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
KR20250099259A (ko) * 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN110869053A (zh) * 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
TW202102221A (zh) 2021-01-16
AU2025256180A1 (en) 2025-11-13
JP2022524576A (ja) 2022-05-09
US20230027066A1 (en) 2023-01-26
KR20260049872A (ko) 2026-04-14
BR112021017198A2 (pt) 2021-11-16
EP3941473A1 (en) 2022-01-26
EP4763281A2 (en) 2026-06-24
WO2020188505A1 (en) 2020-09-24
IL285910A (en) 2021-10-31
AU2020243514A1 (en) 2021-08-26
SG11202108810YA (en) 2021-10-28
CA3129024A1 (en) 2020-09-24
PH12021551975A1 (en) 2022-07-04
CN121489955A (zh) 2026-02-10
CN113840607A (zh) 2021-12-24
MX2021009488A (es) 2021-09-21
KR20210142004A (ko) 2021-11-23
JP2025084777A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
US20090318469A1 (en) Use of Flibanserin for the Treatment of Sexual Disorders in Females
McKeage Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms
JP2025084777A (ja) 過活動膀胱を処置するためのビベグロンの使用
MX2012011395A (es) Metodos de mejoramiento de la calidad del sueño.
JP2025032143A (ja) 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
JP6355921B2 (ja) コカイン嗜癖の治療
JP2021530568A (ja) 自閉症を処置するための組成物および方法
EP1622450A2 (en) Method for promoting uninterrupted sleep by administration of trospium chloride
EP4422628A1 (en) Methods of treating agitation associated with alzheimer's disease
CN109310691A (zh) 用于快速开始抗抑郁作用的给药方案
US20130253067A1 (en) Method of treating bladder disorders
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
US20240358693A1 (en) Methods of treating pain
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря
EP4673123A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
BR122024021845A2 (pt) Usos de vibegron para tratar sintomas de bexiga hiperativa e reduzir ou diminuir as micções